The following corrective actions were found deficient: a.
Inspection Record
GlaxoSmithKline Biologicals SA — FDA 483 Findings
Inspectors Debra M. Emerson · Susan Jackson · Leslie Wagner and 1 moreThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Failure to thoroughly investigate the presence of) _,,, in the Water for Injection (WFI) | os where sterile bukh is manufactured.
The following equipment maintenance issues were on observed on June 7, 2019 in the) a | ww manufacturing building: a.
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that in-process materials conform to appropriate standards of purity.
There is a lack of documentation approved by the Quality Unit to support operating outside of your routine operations.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.